Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple -Negative Breast Cancer|Estrogen Receptor Negative|HER2/Neu Negative|Anatomic Stage IV Breast Cancer AJCC|Progesterone Receptor Negative
Interventions: PROCEDURE: Biopsy|PROCEDURE: Chemokine Modulation Therapy|DRUG: Celecoxib|BIOLOGICAL: Recombinant Interferon Alfa-2b|DRUG: Rintatolimod|BIOLOGICAL: Pembrolizumab
Sponsor: Roswell Park Cancer Institute
Collaborators: AIM ImmunoTech Inc.